In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1259-1266

  Viganò, Alessandra ^a   Mora, Stefano ^b   Giacomet, Vania ^a   Stucchi, Sara ^a   Manfredini, Valeria ^a   Gabiano, Clara ^c   Salvini, Filippo ^d   Cellini, Monica ^e   Tamburrini, Enrica ^f   Puzzovio, Maria ^b   Zuccotti, Gian Vincenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TENOFOVIR DISOPROXIL;

ARTICLE; BONE INJURY; BONE METABOLISM; BONE TOXICITY; CHILD; CHILD GROWTH; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GESTATIONAL AGE; GROWTH RATE; GROWTH RETARDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LOW BIRTH WEIGHT; MALE; MULTICENTER STUDY; PERINATAL DEVELOPMENT; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROCONVERSION; TERATOGENICITY; TOXICITY;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE AND BONES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FETUS; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; ITALY; MALE; OBSERVATION; PHOSPHONIC ACIDS; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 83455179365     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1909     Document Type: Article

References (24)

1. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8:164-172. (Pubitemid 47121761)
2. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
3. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273-1281. (Pubitemid 46883481)
4. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43:1071-1087. (Pubitemid 40013177)
5. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. (Updated 24 May 2010. Accessed 9 December 2010.) Available from http://aidsinfo.nih.gov/ContentFiles/ PerinatalGL.pdf
6. European AIDS Clinical Society. Guidelines for clinical management and treatment of HIV infected adults in Europe (Updated 12 May 2010. Accessed 9 December 2010.) Available from http://www.europeanaidsclinicalsociety.org/ guidelinespdf/1-Treatment-of-HIV-Infected-Adults.pdf
7. Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:323-333. (Pubitemid 29143025)
8. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Foetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29:207-220. (Pubitemid 34208529)
9. Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother 2008; 42:1581-1585.
10. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: associations with low birth weight and early growth in HIV-exposed uninfected infants. 2nd International Workshop on HIV Pediatrics. 16-17 July 2010, Vienna, Austria. Abstract O-01.
11. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. (Updated 16 August 2010. Accessed 10 December 2010.) Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf
12. Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006; 29:581-593. (Pubitemid 44446267)
13. Overton ET, Sungkanuparph S, Nurutdinova D, Powderly WG. Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. AIDS 2005; 19:1439. (Pubitemid 41800686)
14. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19:63-67. (Pubitemid 40111019)
15. Largo RH, Wälli R, Duc G, Fanconi A, Prader A. Evaluation of perinatal growth. Helv Paediatr Acta 1980; 35:419-436.
16. Mora S, Prinster C, Bellini A, et al. Bone turnover in neonates: changes of urinary excretion rate of collagen type I cross-linked peptides during the first days of life and influence of gestational age. Bone 1997; 20:563-566. (Pubitemid 27270472)
17. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 1 December 2009. Accessed 10 December 2010.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
18. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008; 29:535-559.
19. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711-e718. (Pubitemid 46089998)
20. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152:582-584. (Pubitemid 351381047)
21. Barkmann R, Rohrschneider W, Vierling M, et al. German pediatric reference data for quantitative transverse transmission ultrasound of finger phalanges. Osteoporos Int 2002; 13:55-61. (Pubitemid 34157832)
22. Christoforidis A, Papadopoulou E, Dimitriadou M, et al. Reference values for quantitative ultrasonography (QUS) of radius and tibia in healthy greek pediatric population: clinical correlations. J Clin Densitom 2009; 12:360-368.
23. McDevitt H, Ahmed SF. Quantitative ultrasound assessment of bone health in the neonate. Neonatology 2007; 91:2-11. (Pubitemid 46141195)
24. Mora S, Viganò A, Cafarelli L, et al. Applicability of quantitative ultrasonography of the radius and tibia in HIV-infected children and adolescents. J Acquir Immune Defic Syndr 2009; 51:588-592.